Davis Dawn Marie, Borok Jenna, Udkoff Jeremy, Lio Peter, Spergel Jonathan
Department of Dermatology and Pediatrics, Mayo Clinic Rochester, Minnesota, USA.
Division of Pediatric and Adolescent Dermatology, Rady Children's Hospital, San Diego, California, USA.
Semin Cutan Med Surg. 2017 Sep;36(3):118-123. doi: 10.12788/j.sder.2017.027.
The majority of atopic dermatitis (AD) patients respond satisfactorily to gentle bathing, frequent moisturizing, and topical medications. Second-line therapies for AD should be used in recalcitrant cases or in patients with uncontrolled disease despite compliance with first-line measures and avoidance of allergens. Recommended advanced therapies include phototherapy, especially narrowband ultraviolet B, systemic immunosuppressants, and a new biologic agent. Few studies have compared head-to-head efficacy of the different immunosuppressant therapies such as cyclosporine, methotrexate, azathioprine and mycophenolate mofetil. Therefore, the agent used is based on provider and patient preferences and can be decided on a case-by-case basis.
大多数特应性皮炎(AD)患者对温和洗浴、频繁保湿及外用药物治疗反应良好。AD的二线治疗应在难治性病例中使用,或用于尽管遵循一线治疗措施并避免接触过敏原但疾病仍未得到控制的患者。推荐的进阶治疗包括光疗,尤其是窄谱中波紫外线、全身免疫抑制剂及一种新型生物制剂。很少有研究对不同免疫抑制剂疗法(如环孢素、甲氨蝶呤、硫唑嘌呤和霉酚酸酯)的直接疗效进行比较。因此,所使用的药物基于医疗服务提供者和患者的偏好,可逐案决定。